Allelix deal

AXB will continue development of the bone restoration treatment for postmenopausal osteoporosis, with IND filings for Phase II trials in the U.S. and Canada anticipated in the first quarter of 1995.

Under the 1989 agreement, Glaxo Canada had invested about $9 million in the drug's development, including $6 million for Phase I trials in Holland. ...